Ventas, Inc.
VTR
NYSE·Real Estate·REIT - Healthcare Facilities·Mkt cap $43.9B
$90.27
▼ -2.00%
P/E
322.39
Mkt Cap
$43.9B
52-Wk Range
$66.54–$101.60
52-Week Range
$66.54 - $101.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 32.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified Healthcare Real Estate Portfolio
- Strategic Partnerships with Leading Healthcare Providers
- Experienced Management Team
- Strong Balance Sheet and Capital Allocation Strategy
Bear Case
2 risks
- Low volatility (beta 0.7).
- Extreme premium - high expectations embedded
Growth
Stable outlook
Aging Population Demographics
Value
Extreme premium - high expectations embedded
Momentum
Strong
+10.1% over 3m
Quality
Loss-making
Solid business
Dividend
Solid
2.22% yield
Smart-money signal
Who's buying VTR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 29, 2026
Reported EPS of $0.14 vs $0.14 consensus (-1.6% surprise). Revenue of $1.7B vs $1.7B expected (+2.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.6%
Revenue trend · last 8Q
—
+11%
+13%
+18%
+20%
+22%
+22%
+22%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.2B
$1.3B
$1.4B
$1.4B
$1.5B
$1.6B
$1.7B
$1.7B
Margins · last 8Q
Gross
-37.9%
Operating
-11.1%
Profit
-3.2%
Wall Street consensus
13 analysts · 77% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
77%
Hold
23%
Sell
0%
Median Price Target
—
Latest: Scotiabank · Sep 2, 2026
vs Industry
How VTR stacks vs REIT - Healthcare Facilities
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related